Clinical trial

Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet.

NCT00645502

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2003-06-01

PhasePHASE1

Study timeline

Study start (unknown)2003-06-01Date precision: month

Registry last updated2010-04-26

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophreniaverified · MONDO: schizophrenia

Schizoaffective Disordersunresolved

Interventions

risperidoneDRUG · verified · RxNorm: risperidone

Sponsors & collaborators

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00645502 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.